Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 243

1.

Discovery of a potent and selective oral inhibitor of ERK1/2 (AZD0364) that is efficacious in both monotherapy and combination therapy in models of non-small cell lung cancer (NSCLC).

Ward RA, Anderton MJ, Bethel PA, Breed J, Cook C, Davies E, Dobson A, Dong Z, Fairley G, Farrington P, Feron LJ, Flemington V, Gibbons FD, Graham MA, Greenwood RDR, Hanson L, Hopcroft P, Howells R, Hudson J, James M, Jones CD, Jones C, Li Y, Lamont S, Lewis RJ, Lindsay NA, McCabe JF, McGuire TM, Rawlins PB, Roberts K, Sandin L, Simpson I, Swallow S, Tang J, Tomkinson G, Tonge M, Wang Z, Zhai B.

J Med Chem. 2019 Nov 11. doi: 10.1021/acs.jmedchem.9b01295. [Epub ahead of print]

PMID:
31710489
2.

Recurrent spontaneous pneumothoraces and vaping in an 18-year-old man: a case report and review of the literature.

Bonilla A, Blair AJ, Alamro SM, Ward RA, Feldman MB, Dutko RA, Karagounis TK, Johnson AL, Folch EE, Vyas JM.

J Med Case Rep. 2019 Sep 9;13(1):283. doi: 10.1186/s13256-019-2215-4.

3.

CD82 controls CpG-dependent TLR9 signaling.

Khan NS, Lukason DP, Feliu M, Ward RA, Lord AK, Reedy JL, Ramirez-Ortiz ZG, Tam JM, Kasperkovitz PV, Negoro PE, Vyas TD, Xu S, Brinkmann MM, Acharaya M, Artavanis-Tsakonas K, Frickel EM, Becker CE, Dagher Z, Kim YM, Latz E, Ploegh HL, Mansour MK, Miranti CK, Levitz SM, Vyas JM.

FASEB J. 2019 Nov;33(11):12500-12514. doi: 10.1096/fj.201901547R. Epub 2019 Aug 13.

PMID:
31408613
4.

Tetraspanin CD82 Organizes Dectin-1 into Signaling Domains to Mediate Cellular Responses to Candida albicans.

Tam JM, Reedy JL, Lukason DP, Kuna SG, Acharya M, Khan NS, Negoro PE, Xu S, Ward RA, Feldman MB, Dutko RA, Jeffery JB, Sokolovska A, Wivagg CN, Lassen KG, Le Naour F, Matzaraki V, Garner EC, Xavier RJ, Kumar V, van de Veerdonk FL, Netea MG, Miranti CK, Mansour MK, Vyas JM.

J Immunol. 2019 Jun 1;202(11):3256-3266. doi: 10.4049/jimmunol.1801384. Epub 2019 Apr 22.

PMID:
31010852
5.

Predicting protein-ligand binding affinity and correcting crystal structures with quantum mechanical calculations: lactate dehydrogenase A.

Lukac I, Abdelhakim H, Ward RA, St-Gallay SA, Madden JC, Leach AG.

Chem Sci. 2019 Jan 4;10(7):2218-2227. doi: 10.1039/c8sc04564j. eCollection 2019 Feb 21.

6.

Membrane innovation: closer to native kidneys.

Storr M, Ward RA.

Nephrol Dial Transplant. 2018 Oct 1;33(suppl_3):iii22-iii27. doi: 10.1093/ndt/gfy228. Review.

7.

Multi-disciplinary approach to perioperative risk assessment and post-transplant management for liver transplantation in a patient at risk for Brugada syndrome.

Ward RA, Ajayi T, Aylward T, Byrns J, Summers BB, Wilder J.

J Perioper Pract. 2019 May;29(5):140-146. doi: 10.1177/1750458918796013. Epub 2018 Sep 13.

PMID:
30212282
8.

Hypoalbuminemia: a price worth paying for improved dialytic removal of middle-molecular-weight uremic toxins?

Ward RA, Beck W, Bernardo AA, Alves FC, Stenvinkel P, Lindholm B.

Nephrol Dial Transplant. 2019 Jun 1;34(6):901-907. doi: 10.1093/ndt/gfy236.

PMID:
30102329
9.

Structure-based design of targeted covalent inhibitors.

Lonsdale R, Ward RA.

Chem Soc Rev. 2018 Jun 5;47(11):3816-3830. doi: 10.1039/c7cs00220c. Review.

PMID:
29620097
10.

Toxicological and pharmacological assessment of AGEN1884, a novel human IgG1 anti-CTLA-4 antibody.

Gombos RB, Gonzalez A, Manrique M, Chand D, Savitsky D, Morin B, Breous-Nystrom E, Dupont C, Ward RA, Mundt C, Duckless B, Tang H, Findeis MA, Schuster A, Waight JD, Underwood D, Clarke C, Ritter G, Merghoub T, Schaer D, Wolchok JD, van Dijk M, Buell JS, Cuillerot JM, Stein R, Drouin EE, Wilson NS.

PLoS One. 2018 Apr 4;13(4):e0191926. doi: 10.1371/journal.pone.0191926. eCollection 2018.

11.

Regulatory Considerations for Hemodiafiltration in the United States.

Ward RA, Vienken J, Silverstein DM, Ash S, Canaud B; Kidney Health Initiative HDF Workgroup.

Clin J Am Soc Nephrol. 2018 Sep 7;13(9):1444-1449. doi: 10.2215/CJN.12641117. Epub 2018 Mar 6.

12.

Hemodiafiltration to Address Unmet Medical Needs ESKD Patients.

Canaud B, Vienken J, Ash S, Ward RA; Kidney Health Initiative HDF Workgroup.

Clin J Am Soc Nephrol. 2018 Sep 7;13(9):1435-1443. doi: 10.2215/CJN.12631117. Epub 2018 Mar 6.

13.

Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions.

Floc'h N, Martin MJ, Riess JW, Orme JP, Staniszewska AD, Ménard L, Cuomo ME, O'Neill DJ, Ward RA, Finlay MRV, McKerrecher D, Cheng M, Vang DP, Burich RA, Keck JG, Gandara DR, Mack PC, Cross DAE.

Mol Cancer Ther. 2018 May;17(5):885-896. doi: 10.1158/1535-7163.MCT-17-0758. Epub 2018 Feb 26.

14.

Expanding the Armory: Predicting and Tuning Covalent Warhead Reactivity.

Lonsdale R, Burgess J, Colclough N, Davies NL, Lenz EM, Orton AL, Ward RA.

J Chem Inf Model. 2017 Dec 26;57(12):3124-3137. doi: 10.1021/acs.jcim.7b00553. Epub 2017 Nov 21.

PMID:
29131621
15.

Identification and Characterization of Dual Inhibitors of the USP25/28 Deubiquitinating Enzyme Subfamily.

Wrigley JD, Gavory G, Simpson I, Preston M, Plant H, Bradley J, Goeppert AU, Rozycka E, Davies G, Walsh J, Valentine A, McClelland K, Odrzywol KE, Renshaw J, Boros J, Tart J, Leach L, Nowak T, Ward RA, Harrison T, Andrews DM.

ACS Chem Biol. 2017 Dec 15;12(12):3113-3125. doi: 10.1021/acschembio.7b00334. Epub 2017 Nov 28.

PMID:
29131570
16.

A High-Throughput Screening Triage Workflow to Authenticate a Novel Series of PFKFB3 Inhibitors.

St-Gallay SA, Bennett N, Critchlow SE, Curtis N, Davies G, Debreczeni J, Evans N, Hardern I, Holdgate G, Jones NP, Leach L, Maman S, McLoughlin S, Preston M, Rigoreau L, Thomas A, Turnbull AP, Walker G, Walsh J, Ward RA, Wheatley E, Winter-Holt J.

SLAS Discov. 2018 Jan;23(1):11-22. doi: 10.1177/2472555217732289. Epub 2017 Sep 25.

PMID:
28945981
17.

Endocytosis is required for exocytosis and priming of respiratory burst activity in human neutrophils.

Creed TM, Tandon S, Ward RA, McLeish KR.

Inflamm Res. 2017 Oct;66(10):891-899. doi: 10.1007/s00011-017-1070-2. Epub 2017 Jun 21.

PMID:
28638979
18.

Re-Examining Neutrophil Participation in GN.

Caster DJ, Powell DW, Miralda I, Ward RA, McLeish KR.

J Am Soc Nephrol. 2017 Aug;28(8):2275-2289. doi: 10.1681/ASN.2016121271. Epub 2017 Jun 15. Review. Erratum in: J Am Soc Nephrol. 2017 Oct;28(10 ):3129.

19.

The structure-guided discovery of osimertinib: the first U.S. FDA approved mutant selective inhibitor of EGFR T790M.

Butterworth S, Cross DAE, Finlay MRV, Ward RA, Waring MJ.

Medchemcomm. 2017 May 10;8(5):820-822. doi: 10.1039/c7md90012k. eCollection 2017 May 1.

20.

Single fraction spine stereotactic ablative body radiotherapy with volumetric modulated arc therapy.

Gestaut MM, Thawani N, Kim S, Gutti VR, Jhavar S, Deb N, Morrow A, Ward RA, Huang JH, Patel M.

J Neurooncol. 2017 May;133(1):165-172. doi: 10.1007/s11060-017-2428-6. Epub 2017 Apr 13.

PMID:
28409420
21.

Structure-Guided Discovery of Potent and Selective Inhibitors of ERK1/2 from a Modestly Active and Promiscuous Chemical Start Point.

Ward RA, Bethel P, Cook C, Davies E, Debreczeni JE, Fairley G, Feron L, Flemington V, Graham MA, Greenwood R, Griffin N, Hanson L, Hopcroft P, Howard TD, Hudson J, James M, Jones CD, Jones CR, Lamont S, Lewis R, Lindsay N, Roberts K, Simpson I, St-Gallay S, Swallow S, Tang J, Tonge M, Wang Z, Zhai B.

J Med Chem. 2017 Apr 27;60(8):3438-3450. doi: 10.1021/acs.jmedchem.7b00267. Epub 2017 Apr 14.

PMID:
28376306
22.

Frontline Science: Tumor necrosis factor-α stimulation and priming of human neutrophil granule exocytosis.

McLeish KR, Merchant ML, Creed TM, Tandon S, Barati MT, Uriarte SM, Ward RA.

J Leukoc Biol. 2017 Jul;102(1):19-29. doi: 10.1189/jlb.3HI0716-293RR. Epub 2017 Jan 17.

23.

Optimization of Highly Kinase Selective Bis-anilino Pyrimidine PAK1 Inhibitors.

McCoull W, Hennessy EJ, Blades K, Chuaqui C, Dowling JE, Ferguson AD, Goldberg FW, Howe N, Jones CR, Kemmitt PD, Lamont G, Varnes JG, Ward RA, Yang B.

ACS Med Chem Lett. 2016 Sep 14;7(12):1118-1123. eCollection 2016 Dec 8.

24.

Fibrous Dysplasia in the Calcaneus.

Bartley J, Munroe SM, Ward RA.

Foot Ankle Spec. 2017 Feb;10(1):72-74. doi: 10.1177/1938640016656237. Epub 2016 Jul 7.

PMID:
27325625
25.

Inadequate care of elderly patient with dementia.

Ward RA.

Nurs N Z. 2015 Nov;21(10):38. No abstract available.

PMID:
26717637
26.

Identification of DYRK1B as a substrate of ERK1/2 and characterisation of the kinase activity of DYRK1B mutants from cancer and metabolic syndrome.

Ashford AL, Dunkley TP, Cockerill M, Rowlinson RA, Baak LM, Gallo R, Balmanno K, Goodwin LM, Ward RA, Lochhead PA, Guichard S, Hudson K, Cook SJ.

Cell Mol Life Sci. 2016 Feb;73(4):883-900. doi: 10.1007/s00018-015-2032-x. Epub 2015 Sep 7.

27.

The Risk of Cyanobacterial Toxins in Dialysate: What Do We Know?

Hilborn ED, Ward RA.

Semin Dial. 2016 Jan-Feb;29(1):15-8. doi: 10.1111/sdi.12420. Epub 2015 Aug 19.

PMID:
26288252
28.

Close To You? How Parent-Adult Child Contact Is Influenced by Family Patterns.

Deane G, Spitze G, Ward RA, Zhuo YA.

J Gerontol B Psychol Sci Soc Sci. 2016 Mar;71(2):344-57. doi: 10.1093/geronb/gbv036. Epub 2015 May 29.

29.

Structure-Guided Design of Highly Selective and Potent Covalent Inhibitors of ERK1/2.

Ward RA, Colclough N, Challinor M, Debreczeni JE, Eckersley K, Fairley G, Feron L, Flemington V, Graham MA, Greenwood R, Hopcroft P, Howard TD, James M, Jones CD, Jones CR, Renshaw J, Roberts K, Snow L, Tonge M, Yeung K.

J Med Chem. 2015 Jun 11;58(11):4790-801. doi: 10.1021/acs.jmedchem.5b00466. Epub 2015 May 28.

PMID:
25977981
30.

Discovery and optimization of a novel series of Dyrk1B kinase inhibitors to explore a MEK resistance hypothesis.

Kettle JG, Ballard P, Bardelle C, Cockerill M, Colclough N, Critchlow SE, Debreczeni J, Fairley G, Fillery S, Graham MA, Goodwin L, Guichard S, Hudson K, Ward RA, Whittaker D.

J Med Chem. 2015 Mar 26;58(6):2834-44. doi: 10.1021/acs.jmedchem.5b00098. Epub 2015 Mar 12.

PMID:
25738750
31.

Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE): 2014 update.

Tobe SW, Stone JA, Walker KM, Anderson T, Bhattacharyya O, Cheng AY, Gregoire J, Gubitz G, L'Abbé M, Lau DC, Leiter LA, Oh P, Padwal R, Poirier L, Selby P, Tremblay M, Ward RA, Hua D, Liu PP; C-CHANGE Initiative.

CMAJ. 2014 Nov 18;186(17):1299-305. doi: 10.1503/cmaj.140387. Epub 2014 Oct 20. No abstract available.

32.

Behavioral development and sociodemographics of infants and young children at higher and lower risk for autism spectrum disorders.

Feldman MA, Hendry AM, Ward RA, Hudson M, Liu X.

J Autism Dev Disord. 2015 May;45(5):1167-75. doi: 10.1007/s10803-014-2277-5.

PMID:
25326257
33.

Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor.

Finlay MR, Anderton M, Ashton S, Ballard P, Bethel PA, Box MR, Bradbury RH, Brown SJ, Butterworth S, Campbell A, Chorley C, Colclough N, Cross DA, Currie GS, Grist M, Hassall L, Hill GB, James D, James M, Kemmitt P, Klinowska T, Lamont G, Lamont SG, Martin N, McFarland HL, Mellor MJ, Orme JP, Perkins D, Perkins P, Richmond G, Smith P, Ward RA, Waring MJ, Whittaker D, Wells S, Wrigley GL.

J Med Chem. 2014 Oct 23;57(20):8249-67. doi: 10.1021/jm500973a. Epub 2014 Oct 1.

PMID:
25271963
34.

AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.

Cross DA, Ashton SE, Ghiorghiu S, Eberlein C, Nebhan CA, Spitzler PJ, Orme JP, Finlay MR, Ward RA, Mellor MJ, Hughes G, Rahi A, Jacobs VN, Red Brewer M, Ichihara E, Sun J, Jin H, Ballard P, Al-Kadhimi K, Rowlinson R, Klinowska T, Richmond GH, Cantarini M, Kim DW, Ranson MR, Pao W.

Cancer Discov. 2014 Sep;4(9):1046-61. doi: 10.1158/2159-8290.CD-14-0337. Epub 2014 Jun 3.

35.

Extracorporeal removal of uremic toxins: can we still do better?

Eloot S, Ledebo I, Ward RA.

Semin Nephrol. 2014 Mar;34(2):209-27. doi: 10.1016/j.semnephrol.2014.02.011. Epub 2014 Feb 18. Review.

PMID:
24780474
36.

Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR).

Ward RA, Anderton MJ, Ashton S, Bethel PA, Box M, Butterworth S, Colclough N, Chorley CG, Chuaqui C, Cross DA, Dakin LA, Debreczeni JÉ, Eberlein C, Finlay MR, Hill GB, Grist M, Klinowska TC, Lane C, Martin S, Orme JP, Smith P, Wang F, Waring MJ.

J Med Chem. 2013 Sep 12;56(17):7025-48. doi: 10.1021/jm400822z. Epub 2013 Aug 30.

PMID:
23930994
37.

Change in perceived age in middle and later life.

Ward RA.

Int J Aging Hum Dev. 2013;76(3):251-67.

PMID:
23781706
38.

Technical note: proteomic approaches to fundamental questions about neutrophil biology.

McLeish KR, Merchant ML, Klein JB, Ward RA.

J Leukoc Biol. 2013 Oct;94(4):683-92. doi: 10.1189/jlb.1112591. Epub 2013 Mar 7. Review.

39.

Inhibition of neutrophil exocytosis ameliorates acute lung injury in rats.

Uriarte SM, Rane MJ, Merchant ML, Jin S, Lentsch AB, Ward RA, McLeish KR.

Shock. 2013 Mar;39(3):286-92. doi: 10.1097/SHK.0b013e318282c9a1.

40.

Exocytosis of neutrophil granule subsets and activation of prolyl isomerase 1 are required for respiratory burst priming.

McLeish KR, Uriarte SM, Tandon S, Creed TM, Le J, Ward RA.

J Innate Immun. 2013;5(3):277-89. doi: 10.1159/000345992. Epub 2013 Jan 26.

41.

Online haemodiafiltration: definition, dose quantification and safety revisited.

Tattersall JE, Ward RA; EUDIAL group.

Nephrol Dial Transplant. 2013 Mar;28(3):542-50. doi: 10.1093/ndt/gfs530. Epub 2013 Jan 22.

PMID:
23345621
42.

Cysteine protease inhibition by nitrile-based inhibitors: a computational study.

Quesne MG, Ward RA, de Visser SP.

Front Chem. 2013 Dec 27;1:39. doi: 10.3389/fchem.2013.00039. eCollection 2013.

43.

Dialysate quality: new standards require a new approach to compliance.

Fendley DA, Ward RA.

Semin Dial. 2012 Sep-Oct;25(5):510-5. doi: 10.1111/sdi.12007.

PMID:
22994601
44.

Atypical intradermal smooth muscle neoplasms (formerly cutaneous leiomyosarcomas): case series, immunohistochemical profile and review of the literature.

Hall BJ, Grossmann AH, Webber NP, Ward RA, Tripp SR, Rosenthal HG, Florell SR, Randall RL, Cockerell CJ, Layfield LJ, Liu T.

Appl Immunohistochem Mol Morphol. 2013 Mar;21(2):132-8. doi: 10.1097/PAI.0b013e31825f4af2. Review.

PMID:
22820664
45.

Design and synthesis of novel lactate dehydrogenase A inhibitors by fragment-based lead generation.

Ward RA, Brassington C, Breeze AL, Caputo A, Critchlow S, Davies G, Goodwin L, Hassall G, Greenwood R, Holdgate GA, Mrosek M, Norman RA, Pearson S, Tart J, Tucker JA, Vogtherr M, Whittaker D, Wingfield J, Winter J, Hudson K.

J Med Chem. 2012 Apr 12;55(7):3285-306. doi: 10.1021/jm201734r. Epub 2012 Mar 26.

PMID:
22417091
46.

New AAMI standards for dialysis fluids.

Ward RA.

Nephrol News Issues. 2011 Dec;25(13):33-6. No abstract available.

PMID:
22308832
47.

Dialysate flow rate and delivered Kt/Vurea for dialyzers with enhanced dialysate flow distribution.

Ward RA, Idoux JW, Hamdan H, Ouseph R, Depner TA, Golper TA.

Clin J Am Soc Nephrol. 2011 Sep;6(9):2235-9. doi: 10.2215/CJN.02630311. Epub 2011 Jul 28.

48.

Systematic enumeration of heteroaromatic ring systems as reagents for use in medicinal chemistry.

Ward RA, Kettle JG.

J Med Chem. 2011 Jul 14;54(13):4670-7. doi: 10.1021/jm200338a. Epub 2011 Jun 8.

PMID:
21650161
49.

Granule exocytosis contributes to priming and activation of the human neutrophil respiratory burst.

Uriarte SM, Rane MJ, Luerman GC, Barati MT, Ward RA, Nauseef WM, McLeish KR.

J Immunol. 2011 Jul 1;187(1):391-400. doi: 10.4049/jimmunol.1003112. Epub 2011 Jun 3.

50.

Intraoperative navigation for minimally invasive resection of periarticular and pelvic tumors.

Wu K, Webber NP, Ward RA, Jones KB, Randall RL.

Orthopedics. 2011 May;34(5):372. doi: 10.3928/01477447-20110317-17.

Supplemental Content

Support Center